Quinacrine Treatment of Nitroimidazole-Refractory Giardiasis.

J Infect Dis

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.

Published: May 2022

Background: Limited evidence exists on efficacy and tolerability of quinacrine for nitroimidazole-refractory giardiasis.

Methods: Nitroimidazole-refractory giardiasis cases, defined as microbiologically (microscopy and/or PCR) confirmed treatment failure after 2 courses, during 2008-2020, were retrospectively identified.

Results: Of 87 patients, 54 (62%) had visited India. Quinacrine was used in 54 (62%); 51 received monotherapy and 3 combined with metronidazole. Only 3 had positive stool samples with persisting symptoms after quinacrine treatment (94% parasitological efficacy) and all were cured after a second treatment. One (1.9%) had mild adverse effects recorded.

Conclusions: Quinacrine is an effective treatment for nitroimidazole-refractory giardiasis with good tolerability.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113433PMC
http://dx.doi.org/10.1093/infdis/jiab287DOI Listing

Publication Analysis

Top Keywords

nitroimidazole-refractory giardiasis
12
quinacrine treatment
8
treatment nitroimidazole-refractory
8
quinacrine
5
nitroimidazole-refractory
4
giardiasis background
4
background limited
4
limited evidence
4
evidence exists
4
exists efficacy
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!